Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016
Published Jun 28, 2016
61 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016, provides in depth analysis on Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted pipeline therapeutics.

The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3)
- The report reviews Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) targeted therapeutics

Reaso

  
Source:
Document ID
GMDHC0149TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Overview71
Therapeutics Development84
  Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Products under Development by Stage of Development81
  Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Products under Development by Therapy Area91
  Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Products under Development by Indication102
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Pipeline Products Glance121
  Early Stage Products121
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Products under Development by Companies133
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Products under Development by Universities/Institutes162
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Therapeutics Assessment186
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action191
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Companies Involved in Therapeutics Development247
  Amgen Inc.241
  Axxam SpA251
  Bionomics Limited261
  conoGenetix biosciences GmbH271
  Johnson &Johnson281
  Kineta, Inc.291
  Sevion Therapeutics, Inc.301
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Drug Profiles3117
  BNC-164 Drug Profile311
  cgtx-A Drug Profile321
  cgtx-F Drug Profile331
  cgtx-G Drug Profile341
  dalazatide Drug Profile355
  KPI-150 Drug Profile401
  KPI-190 Drug Profile411
  OSK-1 Drug Profile421
  Recombinant Peptide to Block Kv1.3 Ion Channel for Autoimmune Diseases Drug Profile431
  Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases Drug Profile441
  Small Molecules to Block Kv1.3 Ion Channel for Multiple Sclerosis, Immunology, Inflammatory Bowel Disease and Type 1 Diabetes Drug Profile451
  SVN-001 Drug Profile461
  Synthetic Peptides to Block Potassium Voltage-Gated Channel Subfamily A Member 3 (Kv1.3) for Autoimmune Disorders Drug Profile471
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Dormant Projects482
Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) Featured News &Press Releases5010
  Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus501
  May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus511
  May 12, 2016: KPI Therapeutics Presents Dalazatide Plaque Psoriasis Data at Dermatology Conference511
  Feb 08, 2016: KPI Therapeutics Initiates Research Program In Skin Diseases511
  Feb 08, 2016: KPI Therapeutics Initiates Research Program In Eye Diseases521
  Nov 10, 2015: Kineta, Seattle Children s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus521
  Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting531
  Aug 08, 2015: Kineta Presents Updated Data on Dalazatide Clinical Trial at 12th World Congress on Inflammation541
  Jun 17, 2015: ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients with Lupus541
  Jun 09, 2015: Kineta To Give Update On Dalazatide Clinical Trial Results At BIO International Meeting551
  Jun 05, 2015: Sevion Therapeutics to Present at International Antibody Meeting551
  May 05, 2015: Kineta Announces Promising Top-line Clinical Results for Dalazatide; Target Implicated in Broad Array of Autoimmune Diseases561
  May 04, 2015: Sevion Therapeutics Presents Cow Antibody Platform at PEGS 2015571
  Apr 21, 2015: Kineta, University of Groningen Present New, Positive Data for Dalazatide in ANCA Vasculitis, an Orphan Disease581
  Mar 19, 2015: Kineta s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases582
Appendix602
  Methodology601
  Coverage601
  Secondary Research601
  Primary Research601
  Expert Panel Validation601
  Contact Us601
  Disclaimer611

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Potassium-Voltage-Gated-Channel-Subfamily-A-Member-3-Voltage-Gated-Potassium-Channel-Subunit-Kv1-3-or-KCNA3-Pipeline-Review-H1-2016-2088-16050>
  
APA:
Global Markets Direct - Market Research. (2016). Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Potassium-Voltage-Gated-Channel-Subfamily-A-Member-3-Voltage-Gated-Potassium-Channel-Subunit-Kv1-3-or-KCNA3-Pipeline-Review-H1-2016-2088-16050>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.